See more : Namibia Critical Metals Inc. (NMI.V) Income Statement Analysis – Financial Results
Complete financial analysis of UG Healthcare Corporation Limited (8K7.SI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of UG Healthcare Corporation Limited, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Taiwan Sanyo Electric Co.,Ltd. (1614.TW) Income Statement Analysis – Financial Results
- CPN Commercial Growth Leasehold Property Fund (CPNCG.BK) Income Statement Analysis – Financial Results
- Industrials REIT Limited (MLI.L) Income Statement Analysis – Financial Results
- Zhejiang Leapmotor Technology Co., Ltd. (9863.HK) Income Statement Analysis – Financial Results
- Contact Gold Corp. (CGOLF) Income Statement Analysis – Financial Results
UG Healthcare Corporation Limited (8K7.SI)
Industry: Medical - Instruments & Supplies
Sector: Healthcare
About UG Healthcare Corporation Limited
UG Healthcare Corporation Limited, an investment holding company, manufactures and sells disposable gloves. It operates through three segments: Latex Examination Gloves, Nitrile Examination Gloves, and Other Ancillary Products. The company offers latex examination gloves that comprise single chlorinated and double chlorinated polymer coated gloves, as well as nitrile examination gloves. It also distributes ancillary products, including surgical gloves, vinyl and cleanroom disposable gloves, face masks, and other medical disposables, as well as shoe covers and other related products; and provides business and management consultancy services. The company's products are used in healthcare, food and beverage, industrial, high technology manufacturing, automotive, research and development, and beauty sectors. It serves customers under the Unigloves brand name in Malaysia, Europe, North America, South America, Africa, and rest of Asia. The company was founded in 1989 and is based in Singapore.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 115.21M | 101.13M | 232.60M | 338.40M | 144.21M | 91.71M | 78.06M | 65.24M | 58.82M | 55.74M | 49.01M |
| Cost of Revenue | 89.34M | 99.69M | 148.21M | 142.24M | 101.69M | 73.00M | 65.30M | 55.57M | 46.13M | 44.19M | 38.81M |
| Gross Profit | 25.87M | 1.45M | 84.39M | 196.16M | 42.52M | 18.72M | 12.76M | 9.67M | 12.69M | 11.55M | 10.20M |
| Gross Profit Ratio | 22.45% | 1.43% | 36.28% | 57.97% | 29.48% | 20.41% | 16.35% | 14.82% | 21.58% | 20.72% | 20.82% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 24.01M | 20.07M | 25.48M | 33.07M | 13.72M | 12.27M | 8.85M | 6.58M | 6.74M | 6.86M | 4.28M |
| Selling & Marketing | 8.48M | 6.50M | 7.75M | 7.31M | 4.00M | 2.82M | 1.80M | 1.78M | 1.33M | 1.33M | 343.00K |
| SG&A | 32.49M | 26.57M | 33.22M | 40.37M | 17.72M | 15.09M | 10.65M | 8.36M | 8.07M | 8.19M | 4.62M |
| Other Expenses | -6.63M | -5.43M | -2.15M | -459.00K | -6.07M | -1.65M | -1.12M | -506.00K | -46.00K | -961.00K | 0.00 |
| Operating Expenses | 25.87M | 26.57M | 33.22M | 40.37M | 17.72M | 15.09M | 10.65M | 8.36M | 8.06M | 8.16M | 4.56M |
| Cost & Expenses | 121.83M | 126.25M | 181.43M | 182.62M | 119.41M | 88.08M | 75.95M | 63.93M | 54.19M | 52.35M | 43.37M |
| Interest Income | 2.01M | 2.15M | 427.00K | 108.00K | 155.00K | 83.00K | 36.00K | 38.00K | 34.00K | 47.00K | 48.00K |
| Interest Expense | 1.28M | 915.00K | 805.00K | 604.00K | 1.99M | 1.62M | 758.00K | 497.00K | 176.00K | 347.00K | 285.00K |
| Depreciation & Amortization | 3.87M | 3.47M | 3.91M | 3.04M | 2.46M | 1.62M | 1.44M | 1.37M | 1.06M | 917.00K | 832.00K |
| EBITDA | -3.94M | -24.53M | 53.37M | 159.46M | 21.35M | 6.00M | 7.25M | 4.43M | 8.71M | 5.22M | 7.25M |
| EBITDA Ratio | -3.42% | -21.40% | 22.98% | 48.18% | 15.61% | 5.74% | 9.27% | 7.00% | 14.11% | 11.09% | 14.46% |
| Operating Income | -6.63M | -25.12M | 49.54M | 160.01M | 20.04M | 3.64M | 5.80M | 3.20M | 7.00M | 3.79M | 5.85M |
| Operating Income Ratio | -5.75% | -24.84% | 21.30% | 47.28% | 13.90% | 3.97% | 7.43% | 4.90% | 11.90% | 6.80% | 11.94% |
| Total Other Income/Expenses | -2.46M | -3.24M | -783.00K | -4.18M | -1.99M | -868.00K | -750.00K | -630.00K | 2.85M | 166.00K | 279.00K |
| Income Before Tax | -9.09M | -28.92M | 48.76M | 159.40M | 18.06M | 2.76M | 5.05M | 2.57M | 7.47M | 3.96M | 6.13M |
| Income Before Tax Ratio | -7.89% | -28.59% | 20.96% | 47.10% | 12.52% | 3.01% | 6.47% | 3.94% | 12.70% | 7.10% | 12.51% |
| Income Tax Expense | -308.00K | -1.40M | 8.96M | 39.46M | 2.97M | 546.00K | 734.00K | 389.00K | 1.95M | 1.03M | 1.22M |
| Net Income | -6.06M | -20.73M | 36.80M | 118.77M | 13.40M | 2.51M | 4.34M | 2.44M | 5.45M | 3.16M | 4.90M |
| Net Income Ratio | -5.26% | -20.50% | 15.82% | 35.10% | 9.29% | 2.73% | 5.55% | 3.75% | 9.27% | 5.68% | 10.00% |
| EPS | -0.01 | -0.03 | 0.06 | 0.19 | 0.02 | 0.00 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 |
| EPS Diluted | -0.01 | -0.03 | 0.06 | 0.19 | 0.02 | 0.00 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 |
| Weighted Avg Shares Out | 623.83M | 623.83M | 620.20M | 611.47M | 588.28M | 579.89M | 574.38M | 574.38M | 564.07M | 564.07M | 564.07M |
| Weighted Avg Shares Out (Dil) | 623.83M | 623.83M | 620.20M | 611.47M | 592.26M | 580.05M | 575.37M | 575.92M | 565.98M | 564.07M | 564.07M |
Source: https://incomestatements.info
Category: Stock Reports